Grace Therapeutics (NASDAQ:GRCE) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Grace Therapeutics (NASDAQ:GRCE) released its quarterly earnings data on Thursday. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.01, Zacks reports.

Grace Therapeutics Price Performance

Shares of GRCE stock traded down $0.03 during trading hours on Thursday, hitting $3.45. The company had a trading volume of 13,053 shares, compared to its average volume of 126,855. The stock’s fifty day moving average is $3.74. Grace Therapeutics has a 12 month low of $2.13 and a 12 month high of $4.97. The company has a market cap of $34.98 million, a price-to-earnings ratio of -3.42 and a beta of 1.36.

Grace Therapeutics Company Profile

Grace Therapeutics Inc is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc, formerly known as Acasti Pharma Inc, is based in Princeton, New Jersey.